Mogrify solidifies IP position surrounding core technology and expands platform algorithm to enhance cell conversion

  • Date 4 Jan 2021

Mogrify have announced it has secured the assignment of the foundational intellectual property (IP) underpinning its core direct cell conversion technology (MOGRIFY® V1) and extended the method to allow for the inclusion of new sources of data and more accurate transcription factor predictions (MOGRIFY V2). The expansion of rights has allowed the Company to bring the latest version of the technology in-house.

The MOGRIFY platform utilizes a systematic big-data approach (Rackham et al., Nature Genetics, 2016) developed over a 10-year period via a multi-national research collaboration. By deploying next-generation sequencing and gene regulatory data, the platform enables the prediction of the transcription factors (or small molecules) and culture medium conditions required to produce (ex vivo or in vivo) any target cell type from any source cell type.

The Company’s patent portfolio includes data for over 150 cell types, of which more than 30 cell conversions are covered in the foundational patent filing with two additional conversion specific patents filed covering the production of chondrocytes and fetal cardiomyocytes. Further conversion specific patents are expected in a number of areas relating to the Company’s internal product pipeline.

Specific progress in Mogrify’s intellectual property position includes the assignment and negotiation of commercially enabling terms for the use of the foundational MOGRIFY patent from RIKEN, University of Bristol, and Monash University, which covers the method of direct cell differentiation and exemplified predictions of numerous human cell conversions.

Read more

Join an ambitious, supportive community of world-class scientists, engineers and entrepreneurs

Read more